Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03565146 · ClinicalTrials.gov registry record · NA

Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions

A NA study of Pigmentation, sponsored by Focus Medical.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT03565146 is a NA study of Pigmentation that has completed, run by Focus Medical. The registered enrollment target is 25 participants, below the 43-participant average among 4 other Pigmentation trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03565146, a NA study of Pigmentation, has completed, sponsored by Focus Medical.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

A total of at least 25 healthy subjects at a single site, aged 21-70 years old with congenital or acquired challenging/resistant, age/sun-related flat and benign facial pigmentation with or without hand pigmentation who wish to improve their skin appearance.

Conditions Studied

Interventions

  • DEVICE PiQo4 Laser System

Study Locations (1)

Texas

  • Westlake Dermatology - Austin

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-06-29
Est. Completion 2019-06-05
Phase NA

Sponsor

Focus Medical

3 total trials

What the Registry Record Tells You About NCT03565146

The ClinicalTrials.gov registry entry for NCT03565146 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 4 other Pigmentation trials with a reported enrollment target (42% lower). The listed sponsor is Focus Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pigmentation appearing as the primary indexed condition, and to 1 intervention - of which PiQo4 Laser System is the first listed.

NCT03565146 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03565146 about?

NCT03565146 is a clinical study titled "Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions". A total of at least 25 healthy subjects at a single site, aged 21-70 years old with congenital or acquired challenging/resistant, age/sun-related flat and benign facial pigmentation with or without hand pigmentation who wish to improve their skin appearance.

What is the current status of trial NCT03565146?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2018-06-29. Estimated completion is 2019-06-05.

What conditions does trial NCT03565146 study?

This clinical trial studies the following conditions: Pigmentation.

What interventions are being tested in trial NCT03565146?

The interventions under investigation include: PiQo4 Laser System (DEVICE).

Who is sponsoring clinical trial NCT03565146?

This trial is sponsored by Focus Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03565146 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pigmentation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.